{"entity":{"id":"nct07007728","kind":"trial","name":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","aka":[],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use) and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","summary":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis is a phase 2, interventional study registered as NCT07007728 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 54 participants, started 2025-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Iparomlimab/Tuvonralimab; Bevacizumab + CAPEOX; Surgical resection ± ablation or stereotactic radiotherapy (if applicable). Conditions listed: Colorectal Neoplasms; Secondary Malignant Neoplasm of Liver. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: \"Pathologically confirmed colorectal adenocarcinoma with liver metastases confirmed by pathology or imaging;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07007728","url":"https://clinicaltrials.gov/study/NCT07007728"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","sbrt","thermal-ablation"],"targets":[],"drugs":["bevacizumab-glioma","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07007728","phase":"2","setting":"Efficacy and Safety of Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy in Patients With Right-Sided or RAS-mutant, Microsatellite Stable, Initially Unresectable Colorectal Cancer Liver Metastasis: A Prospective, Open-Label, Single-Arm, Single-Center, Phase II Clinical Trial","sponsor":"Peking University Cancer Hospital & Institute","enrolled":54,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07007728/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}